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A fluorescence anisotropy assay to discover and
characterize ligands targeting the maytansine site
of tubulin
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Microtubule-targeting agents (MTAs) like taxol and vinblastine are among the most suc-
cessful chemotherapeutic drugs against cancer. Here, we describe a fluorescence anisotropy-
based assay that specifically probes for ligands targeting the recently discovered may-
tansine site of tubulin. Using this assay, we have determined the dissociation constants of
known maytansine site ligands, including the pharmacologically active degradation product of
the clinical antibody-drug conjugate trastuzumab emtansine. In addition, we discovered that
the two natural products spongistatin-1 and disorazole Z with established cellular potency
bind to the maytansine site on β-tubulin. The high-resolution crystal structures of
spongistatin-1 and disorazole Z in complex with tubulin allowed the definition of an additional
sub-site adjacent to the pocket shared by all maytansine-site ligands, which could be
exploitable as a distinct, separate target site for small molecules. Our study provides a basis
for the discovery and development of next-generation MTAs for the treatment of cancer.
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The αβ-tubulin heterodimer is the building block ofmicrotubules that, together with F-actin and intermediatefilaments, constitute the cytoskeleton. As such, tubulin is
an important target for antineoplastic drugs like taxol and vin-
blastine1. By perturbing microtubule dynamics during mitosis,
these drugs interfere with mitotic spindle formation and thus cell
division; however, they also act on interphase microtubules and,
as a consequence, affect the intracellular trafficking of important
molecules and organelles, in particular in neurons2,3.
Microtubule-targeting agents (MTAs) can be broadly divided
into microtubule-stabilizing and -destabilizing agents. Six distinct
tubulin-binding sites for ligands have been structurally char-
acterized to date, which are referred to as the taxane, laulimalide/
peloruside, colchicine, vinca, pironetin and maytansine site,
respectively4–7. Molecules that bind to the taxane and laulimalide/
peloruside site stabilize microtubules, while compounds targeting
the colchicine, vinblastine, pironetin or maytansine site destabi-
lize microtubules. Taxane- and vinblastine-site ligands are in
clinical use for cancer therapy, but no drugs have been approved
that target any of the other four binding sites, with the exception
of maytansine that is part of an antibody-drug conjugate (ADC).
Furthermore, the clinical application of approved MTAs is
hampered by their severe toxic side effects and the development
of resistance8.
The maytansine site on tubulin has been discovered only
very recently9. It is a unique site on β-tubulin that is located at
the longitudinal tubulin–tubulin interface in microtubules,
which readily explains the microtubule-destabilizing effects of
maytansine-site ligands. Three distinctly different ligands that
target the maytansine site have been described: maytansine,
PM060184 and rhizoxin9. Maytansine has been successfully
incorporated into the ADC trastuzumab emtansine, which is
approved for the treatment of breast cancer10. In principle, ADCs
can overcome the toxicity problem associated with MTAs; how-
ever, the costs for developing and using ADCs in targeted therapy
are a major drawback11 and the use of traditional anti-tubulin
agents still remains a valuable approach. PM060184 is in phase II
clinical development for the treatment of breast cancers (clin-
icaltrials.gov), while rhizoxin had reached phase II, before being
discontinued for reasons that are poorly understood12.
In this study, we develop a quantitative fluorescence anisotropy
displacement assay based on a fluorescein-labeled maytansine
derivative, with the aim to provide a platform for the
identification and characterization of additional maytansine-site
ligands. We choose the maytansine site because it is
poorly characterized and because no tools are available to char-
acterize the binding of maytansine-site ligands in detail. We
show that the assay is specific for the maytansine site and can
be operated in a high-throughput manner. By using this assay, we
identify two natural products, spongistatin-1 and disorazole Z, as
maytansine-site ligands. We solve the structures of both com-
pounds in complex with tubulin to high resolution by X-ray
crystallography, which allows us to analyze the maytansine site in
great detail. The experimental tools and results presented in this
study should contribute to the discovery and characterization of
maytansine site-directed, small-molecule MTAs for the develop-
ment of next-generation anti-tubulin drugs for the treatment of
cancer.
Results
A fluorescent probe targeting the maytansine site of tubulin. In
this study, we sought to develop a fluorescence anisotropy assay
to identify and determine the tubulin-binding affinities of
maytansine-site ligands. To this end, we prepared a fluorescently
labeled maytansinoid that carries a fluorescein reporter attached
to the 3-OH group of the maytansinol core structure via a
flexible linker moiety (referred to as FcMaytansine (M5)). In
the tubulin–maytansine crystal structure9, the corresponding
N-acetyl-N-methyl-D-alanyl residue in maytansine occupies a
solvent-exposed position that is located remote from the tubulin
surface; thus, the fluorescein-linker moiety was expected not to
interfere with binding of the FcMaytansine probe. As shown in
Fig. 1, FcMaytansine was prepared in two steps from commer-
cially available maytansinol (M1). Details of the synthesis can be
found in the Supplementary Information.
The tubulin-binding properties of FcMaytansine were assessed
by fluorescence anisotropy measurements. Using our experi-
mental setup (see Methods), the addition of increasing amounts
of tubulin (0 to 400 nM) to FcMaytansine (10 nM) led to a
concentration-dependent increase in anisotropy by a factor
of ~1.6 from ~16 mA in the absence of tubulin to ~250 mA at
saturation (Fig. 2a), thus providing an assay with both excellent
dynamic range and signal-to-noise ratio (see also Supplementary
Fig. 1a). We observed that the increase in fluorescence anisotropy
was accompanied by a concomitant increase in the fluorescence
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intensity by a factor of 3.1 ± 0.1. This behavior is well known for
fluorescein derivatives, whose fluorescence properties depend
on the exact pKa value of the carboxyl group, which is often
affected upon binding of a fluorescein-labeled probe to a protein
target13,14. Incubation of samples for 15 and 45 min at 25 °C prior
to measurements resulted in the same anisotropy values,
demonstrating that a pre-incubation time of 15 min was sufficient
for the system to equilibrate (Supplementary Fig. 1b). The
fluorescence anisotropy data were fitted using a single binding site
model, which yielded a dissociation constant, Kd, for the
tubulin–FcMaytansine interaction of 6.8 ± 0.8 nM (mean ± SEM;
n= 5) (Fig. 1b). A Kd ~of 900 nM has been reported previously
for the tubulin–maytansine interaction15; the ~60-fold lower Kd
value that we obtained for FcMaytansine might be due to the
different assay type and conditions used in our study.
To demonstrate that FcMaytansine does indeed specifically
bind to the maytansine site of tubulin, we used X-ray crystal-
lography. FcMaytansine was soaked into a crystal composed of a
complex formed between two αβ-tubulin heterodimers (T2), the
stathmin-like protein RB3 (R) and tubulin tyrosine ligase (TTL)
16,17, and the structure of the T2R–TTL–FcMaytansine complex
was solved at 2.4 Å resolution (Table 1). As shown in Fig. 2c, d,
the structure revealed that the maytansinoid moiety of FcMay-
tansine interacts with the maytansine site of β-tubulin in exactly
the same manner as the parent compound maytansine9. The 3’-
carboxyl group of the fluorescein moiety of FcMaytansine loosely
packs against the tubulin surface that is formed by the side chains
of βVal181, βMet398, βArg401, βAla403 and βPhe404 and
establishes a polar contact with the side chain of βArg401.
Moreover, the fluorescein moiety is oriented such as to allow the
11-chloro substituent of the maytansine core to establish an edge-
on Cl–π interaction with the xanthene ring; this finding may
explain the change in fluorescence intensity observed upon
binding of the FcMaytansine molecule to tubulin (see above).
Next, we performed fluorescence anisotropy competition
experiments with FcMaytansine and the two unlabeled
maytansine-site ligands ansamitocin P3 (a maytansine derivative)
and PM06018418,19. Vinblastine and colchicine were used as
negative controls. The concentrations of FcMaytansine (10 nM)
and tubulin (4 nM) were chosen such that the bound fraction
of FcMaytansine was around 0.5 based on the Kd of the
tubulin–FcMaytansine complex. The mixture was then incubated
with an unlabeled competitor at increasing concentrations prior
to anisotropy measurements. The final dimethyl sulfoxide
(DMSO) concentration in each sample amounted to ~1.2%; as
documented in Supplementary Fig. 1c, the assay tolerates a
DMSO concentration of up to 5%. The plots shown in Fig. 3a, b
demonstrate that FcMaytansine can be fully displaced by the
two maytansine-site ligands ansamitocin P3 and PM060184 in a
dose-dependent manner, but not by vinblastine or colchicine. The
Kd values determined for ansamitocin P3 and PM060184 were
15.0 ± 1.3 nM (mean ± SEM; n= 3) and 111 ± 30 nM (mean ±
SEM; n= 3), respectively.
To assess whether our assay is suitable for high-throughput
screening, we determined its Z-factor20. Samples of 10 nM
FcMaytansine mixed with 400 nM tubulin and of 10 nM
FcMaytansine alone were applied to a 96-well plate and the
anisotropy was measured (Supplementary Fig. 1d). A Z-factor
of 0.97 was calculated from the mean and the standard
deviation anisotropy values, which underpins the excellent
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Fig. 2 Binding of FcMaytansine to tubulin. a, b FcMaytansine (10 nM) anisotropy variation (a) and fraction bound (b) as a function of the tubulin
concentration. The data are from three independent experiments and represent mean ± SEM. The solid lines represent fits to the data (see Methods). c
Crystal structure of the tubulin–FcMaytansine complex. Superposition of FcMaytansine (white/green) and maytansine (orange, PDB ID 4TV8) bound to
tubulin. The superimposed β-tubulin chains are in ribbon, both the ligands and the interacting residues are in stick representation and are labeled. d Close-
up view of the interactions formed by the xanthene-moiety of FcMaytansine. The same display settings as in c are used
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performance of the assay and makes it suitable for high-
throughput screening20.
Together, these results demonstrate that FcMaytansine is a
specific probe that enables to distinguish between ligands binding
the maytansine site or the nearby vinblastine site of tubulin
(Supplementary Fig. 2a). They further establish our fluorescence
anisotropy assay as a powerful, high-throughput qualified tool to
discover and characterize additional maytansine-site ligands.
Analysis of trastuzumab emtansine degradation products. The
maytansine derivative DM1 (Fig. 3c) forms the basis for trastu-
zumab emtansine, one of the two ADCs currently in clinical
use for cancer treatment; specifically, trastuzumab emtansine is
approved for the treatment of HER2-positive metastatic breast
cancer10. In cells, trastuzumab emtansine is ultimately trans-
formed into the lysine conjugate M9 (Fig. 3c) as the pharmaco-
logically active entity by lysosomal degradation of the targeting
antibody carrier10,21. The in vitro cytotoxicity of M9 has been
investigated and the compound is ~450-fold less potent in cellular
assays than the simple methyl thioether of DM1 (S-Me DM1),
most likely as a consequence of reduced cellular uptake22. At the
same time, the intracellular formation of M9 from an anti-
EpCAM-DM1 conjugate in MCF-7 cells has been shown to
correlate with the effects of the conjugate on microtubule dyna-
micity23. While this finding indicates that the cytotoxicity of the
anti-EpCAM-DM1 conjugate is based on M9-mediated sup-
pression of microtubule dynamics, to the best of our knowledge, a
direct interaction of M9 with tubulin has not been demonstrated.
Using our fluorescence anisotropy displacement assay, we have
thus determined the binding affinity of M9 for tubulin.
The DM1-lysine conjugate M9 (Fig. 3c) was prepared
from DM1 according to literature procedures22 (for details,
see Supplementary Information). The reaction produced two
high-performance liquid chromatography (HPLC)-separable, but
slowly interconverting, C9’-diastereoisomers (designated as M9A
and M9B) in an approximately 1:1 ratio, with full equilibration
in phosphate buffer pH 7.2 being observed after 24 h. This finding
is in line with previous data suggesting that the thiol addition
products of N-ethyl maleimide with different biological thiols
(including cysteine and glutathione) readily interconvert even
at neutral pH24. The method used to prepare M9 inevitably leads
to two diastereoisomeric products, due to the formation of an
additional stereocenter at C9’ in the 1,4-addition of DM1 to the
maleimido part of the linker precursor and the inherently non-
selective nature of the reaction. However, the interconversion rate
between M9A and M9B is sufficiently slow to allow the separate
assessment of their tubulin-binding affinities. As shown in Fig. 3d,
both isomers bind to tubulin with comparable Kd values of 12.6 ±
0.4 nM (mean ± SEM; n= 3) and 17.5 ± 1.2 nM (mean ± SEM;
n= 3) for M9A and M9B, respectively, values similar to the one
obtained for the maytansine derivative ansamitocin P3. These
Kd values are in the same ballpark as the one obtained for
FcMaytansine using direct titration experiments (see above),
indicating that the fluorescein moiety does not significantly
influence the affinity of FcMaytansine for tubulin.
Together, these data demonstrate that the affinity ofM9 is very
similar to that of S-Me DM1, which suggests that the difference in
antiproliferative activity when the compounds are added to cells
exogenously is due to differences in cell uptake. In contrast, the
potency of intracellularly generated M9 should be comparable
with that of maytansine (and, thus, of S-Me DM1).
Spongistatin-1 and disorazole Z are maytansine-site ligands.
Based on biochemical experiments, canonical maytansine-site
ligands like maytansine (or its derivative ansamitocin P3) and
Table 1 Data collection and refinement statistics
T2R–TTL–Disorazole Z T2R–TTL–Spongistatin-1 T2R–TTL–FcMaytansine
Data collection
Space group P212121 P212121 P212121
Cell dimensions
a, b, c (Å) 104.4, 157.6, 179.6 105.7, 159.9, 181.0 104.4, 156.7, 181.0
α, β, γ (°) 90, 90, 90 90, 90, 90 90, 90, 90
Resolution (Å) 56.0–2.1 (2.15–2.10) 50.2–2.4 (2.49–2.40) 49.6–2.4 (2.46–2.40)
Rmerge 10.5 (312.6) 16.7 (273.4) 21.6 (258.6)
I/σI 18.5 (0.7) 15.8 (1.1) 10.0 (0.8)
Completeness (%) 100 (99.8) 99.8 (97.5) 100 (99.8)
Redundancy 12.1 (7.9) 16.7 (15.6) 6.8 (6.5)
Refinement
Resolution (Å) 56.0–2.1 48.1–2.4 49.6–2.4
No. of reflections 172,624 115,478 116,054
Rwork/Rfree 17.9/21.3 16.8/21.6 20.1/25.8
No. of atoms
Protein 17,632 17,648 17,542
Ligand 100 180 145
Water 864 572 453
B-factors
Protein 64.8 71.5 62.6
Ligand 115.0 112.4 97.5
Water 63.9 67.7 53.8
R.m.s. deviations
Bond lengths (Å) 0.004 0.004 0.002
Bond angles (°) 0.621 0.677 0.545
*For each structure data were collected from a single crystal
*Values in parentheses are for highest-resolution shell
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rhizoxin had been previously thought to bind to the vinblas-
tine site of tubulin18,25–27. This misassignment can be explained
by the fact that the maytansine and vinblastine sites are located
close to each other and, thus their distinction is not straightfor-
ward (Supplementary Fig. 2a). To assess whether our fluorescence
anisotropy assay would also enable the identification of
additional maytansine site-specific ligands, we tested a small
number of additional compounds, including the natural product
spongistatin-1. Spongistatin-1 is a highly potent tubulin poly-
merization inhibitor that is believed to bind to the vinblas-
tine site on β-tubulin28. Intriguingly, spongistatin-1 readily
displaced FcMaytansine from tubulin in a dose-dependent
manner, revealing a Kd of 9.5 ± 1.9 nM (mean ± SEM; n= 3)
(Fig. 4a, b). Likewise, the potent cytotoxin disorazole Z29, which
belongs to the same family of myxobacterial natural products as
the vinblastine-site ligand disorazole C130, but whose binding to
tubulin had not been investigated previously, interacts with the
maytansine site with a Kd of 576 ± 49 nM (mean ± SEM; n= 3)
(Fig. 4c, d).
To test whether the two compounds indeed bind to the
maytansine site of tubulin, we used our T2R–TTL crystal system
and solved the tubulin–spongistatin-1 and tubulin–disorazole
Z complex structures to 2.4 and 2.1 Å resolution, respectively
(Table 1; Supplementary Fig. 2bc). The two complex structures
revealed that both compounds indeed interact with the
maytansine site on β-tubulin without inducing any significant
conformational changes in the protein (Fig. 4e, f). Spongistatin-1
binds to the maytansine site by establishing a hydrophobic
network between its cyclic core and the side chains of βAla397,
βMet398, βAla403, βPhe404, βVal181 and βTrp407. Its side chain
is buried in a pocket shaped by the side chains of residues
βPro173, βPro175, βGlu183, βPro184 and βGln394, and by
the main chain atoms of βSer178, βThr180 and βVal181. This
accounts for the structure–activity relationship finding that
incorporation of the full side chain is critical for the potent
cytotoxicity of spongistatin-131. The tubulin–spongistatin com-
plex is further stabilized by polar contacts formed between the
main chain carbonyl group of βAsp179 and the hydroxyl group of
the F ring and between the main chain NH group of βVal181
and the hydroxyl group of the B ring of spongistatin.
Furthermore, a weak C-H hydrogen bond exists between C28H
of the molecule and the main chain carbonyl group of βAla397.
The disorazole Z molecule is anchored into the maytansine site by
several hydrophobic contacts to residues βTyr408, βTrp407 and
βPhe404. The complex is further stabilized by polar contacts
between both the oxazole nitrogen and the adjacent carbonyl
group of the ester moiety to the main chain NH groups of
βVal181 and βVal182, respectively. Moreover, both the carbonyl
group of the second ester moiety and the adjacent hydroxyl group
form hydrogen bonds to the side chain amide of βAsn101 and the
backbone carbonyl of βGly100, respectively. These interactions
involve only one half of the disorazole Z molecule. The other half,
with both halves being related by twofold symmetry, is exposed to
the solvent.
Together, these results demonstrate that our fluorescence
anisotropy assay is suitable to identify maytansine-site ligands
with Kd values in the nanomolar range. They further establish
spongistatin-1 and disorazole Z as maytansine-site ligands.
Comprehensive description of the maytansine site of tubulin.
Collectively, the crystal structures of tubulin in complex with
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Fig. 3 Characterization of maytansine-site ligands. a, b Displacement assays for PM060184 (open circles) and ansamitocin P3 (closed circles) (a), and for
vinblastine (closed circles) and colchicine (open circles) (b). cMolecular structure of the trastuzumab emtansine derivativeM9. d Displacement assays for
the two diastereoisomers of M9, M9A (closed circles) and M9B (open circles). The data are from three independent experiments and represent mean ±
SEM. The solid lines represent fits to the data (see Methods)
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spongistatin-1 and disorazole Z together with those of the com-
plexes with maytansine, PM060184, and rhizoxin F9 allowed us to
analyze the interactions of ligands with the maytansine site in
significant detail. To this end, we superimposed all five complex
structures and compared the binding modes of the structurally
distinct ligands (Fig. 5a, b). Maytansine, PM060184 and rhizoxin
F have been previously shown to share three key interaction
points with β-tubulin (denoted I, II and III), which define a
common pharmacophore9. As illustrated in Fig. 5c, points I and
II represent hydrogen bond acceptor sites, mediating interactions
with βAsn102, βGly100 (point I) and with βVal181 (point II),
respectively; point III mediates hydrophobic contacts through
βVal182 and βTyr408. Notably, while disorazole Z binds to
all three common pharmacophore acceptor points, Spongistatin-1
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Fig. 4 Spongistatin-1 and disorazole Z are maytansine-site ligands. a, c Displacement assays for spongistatin-1 (a) and disorazole Z (c). The data are from
three independent experiments and represent mean ± SEM. The solid lines represent fits to the data (see Methods). b, d Molecular structures of
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binds only to point II. However, all five ligands explore addi-
tional, partially common, nearby β-tubulin pockets (Fig. 5c).
Maytansine/disorazole Z, spongistatin-1/disorazole Z and rhi-
zoxin/disorazole Z interact with three distinct pockets located
close to the common pharmacophore point I via a hydrogen bond
acceptor point IA (mediated by βAsn101), a hydrophobic contact
point IB (mediated by βTrp407) and a hydrophobic contact point
IC (mediated by Phe404), respectively. Furthermore, PM060184
and spongistatin-1 both interact with two pockets adjacent to the
common pharmacophore point II via hydrogen bonds (denoted
point IIA; mediated by βAsp179) and hydrophobic contacts
(denoted point IIB; mediated by βPro175 and βPro184). Inter-
estingly, spongistatin-1 establishes two distinct interactions close
to point II via a hydrophobic contact (denoted point IIC; medi-
ated by βMet398) and a weak hydrogen bond (point IID; medi-
ated by βAla397), thereby defining an additional binding mode
that is not observed for any of the other four maytansine-site
ligands. Overall, this analysis provides a comprehensive and
detailed comparison of the tubulin-binding modes of maytansine-
site ligands.
Discussion
In this study, we have established a high-performance assay that
allows the identification and quantitative evaluation of ligands
that specifically bind to the maytansine site of tubulin. Our
FcMaytansine probe enables the screening of ligands with Kd
values in the nanomolar range in a fast, cheap, non-destructive
and easily automatable manner. Using this assay, we determined
the dissociation constants of a number of important maytansine-
site ligands, including the pharmacologically active entity of the
ADC trastuzumab emtansine and the phase II compound
PM060184. We further identified spongistatin-1 and disorazole Z
as canonical maytansine-site ligands and we have structurally
characterized the maytansine site in great detail.
Our results have several implications. Firstly, our experimental
platform will allow the curation of assignments of ligands that
may be thought to bind to the vinblastine site erroneously. We
expect that the number of ligands binding to the maytansine site
will further increase and establish it as a major ligand binding
site on tubulin along with the taxane, colchicine and vinblas-
tine sites. Secondly, our FcMaytansine approach paves the way to
the generation of additional tool compounds to be used in in vitro
and in cellular experiments. The maytansine site of β-tubulin is
exposed at the plus-end of microtubules. Exchanging the fluor-
escein moiety of FcMaytansine by a stronger fluorophore could
thus be used to visualize distal microtubule plus-ends by fluor-
escence microscopy and study the action of single drug molecules
on their molecular target. Thirdly, maytansine derivatives bearing
fluorescent groups other than fluorescein could be used to
develop assays for the identification of low micromolar affinity
binders, as they are typically found in small molecule and frag-
ment libraries. To the best of our knowledge, there are no
structurally simple (as compared to the structurally complex
natural products investigated here), potent maytansine-site lead
compounds available that could potentially be developed into
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(free) drugs for clinical use. On the other hand, the detailed
structural description of the maytansine site may now enable the
rational design of such less complex maytansine-site-directed
MTAs. Overall, our study presents a possible basis for the
development of next-generation anti-tubulin drugs for the treat-
ment of cancer.
Methods
Chemistry and compounds. Details of the synthesis of the fluorescent maytansi-
noid M5 and the DM1-lysine conjugate M9 are reported in the Supplementary
Information (see Supplementary Methods and Supplementary Figs 3-6). The
synthesis of spongistatin-1 and PM060184 are described elsewhere32,33. Disorazol Z
was produced by fermentation as described in the corresponding patent literature
(biologically active compounds obtainable from Sorangium cellulosum, EP 1743897
A1). Ansamitocin P3, colchicine and vinblastine were obtained from Sigma Aldrich.
Maytansinol was purchased from Levena Biopharm, San Diego, USA.
Tubulin-binding of FcMaytansine and competition experiments. The binding
constant of the fluorescent FcMaytansine probe to tubulin was determined by
fluorescence anisotropy titration at 25 °C in black Greiner 384-well, flat-bottom
microplates and in a final volume of 50 µL. 10 nM FcMaytansine in assay buffer
(15 mM PIPES-KOH, pH 6.8, supplemented with 0.3 mM MgCl2 and 0.2 mM
EDTA) was titrated with increasing amounts of tubulin up to 400 nM. The ani-
sotropy and fluorescence values of the free (r= 0.016 ± 0.001, fluorescence= 1
(arbitrary units)) and bound (r= 0.245 ± 0.005, fluorescence= 3.10 ± 0.05 (arbi-
trary units)) states were determined in the absence and presence of 400 nM tubulin,
respectively. The anisotropy was measured using a PHERAstar microplate reader
(BMG Labtech) with the fluorescence polarization module. Samples were equili-
brated at 25 °C for 15 min prior to measurement at 25 °C. Excitation and emission
wavelengths were set to 485 and 528 nm, respectively. The read height and the gain
were adjusted automatically. As a canonical maytansine-site compound we used
ansamitocin P3, a close derivative of the parent compound maytansine. Compar-
ison of the high-resolution tubulin-ansamitocin P3 crystal structure (our own
unpublished results) with that of tubulin–maytansine9 showed that all tubulin-
contacting groups of the two compounds are identical. We thus consider ansa-
mitocin P3 in this context as an excellent substitute for maytansine.
Fluorescence anisotropy competition experiments and analyses were performed
as previously described34 with minor modifications. Samples containing 10 nM
FcMaytansine and 4 nM tubulin in assay buffer were titrated with increasing
amounts of a competitor at 25 °C in black Greiner 384-well, flat-bottom
microplates and in a final volume of 50 µL. Fluorescence anisotropy measurements
were carried out as described above.
In order to calculate the binding constant of FcMaytansine and one of a non-
fluorescent ligand from a competition experiment, the fractional saturation, νb, of
FcMaytansine has to be determined34. Binding of FcMaytansine to tubulin was
measured through changes in its anisotropy. The anisotropy of a mixture of free
and bound FcMaytansine can be expressed as
r ¼ Fb  rbþ Ff  rf ; ð1Þ
where r is the measured anisotropy, Ff and Fb are the fractional fluorescence
intensities of free and bound FcMaytansine, respectively, rf is the anisotropy of the
free FcMaytansine, and rb is the anisotropy of the bound FcMaytansine.
In the simplest case of a fluorescent probe with no quantum yield difference
between the bound and the free state35, the fraction of bound (νb) and free (νf)
fluorophore coincides with the fluorescence fractions for the bound and free
fluorophore (Fb and Ff, respectively). Employing Eq. 1 and knowing that the sum
of the fluorescence fractions is 1 by definition, we obtain
νb ¼ rrfð Þ= rb rfð Þ: ð2Þ
However, FcMaytansine does not exhibit this behavior, because there is a 3.1 ±
0.1-fold difference between the fluorescence intensity of the bound and free
FcMaytansine. In this case the fluorescence fraction is weighted by the change in
fluorescence intensity according to
Fb ¼ νb  Ib = Itð Þ; ð3Þ
where Ib is the fluorescence intensity of bound FcMaytansine and It is the total
fluorescence intensity. A similar expression applies to free FcMaytasine. Given
Eqs. 1 and 3
r ¼ If= It  νf  rfð Þ þ Ib = It  νb  rbð Þ; ð4Þ
where If is the fluorescence intensity of free FcMaytansine and νf is the fractional
saturation of free FcMaytansine. Since the sum of the fractions free (νf) and bound
(νb) ligand is 1 and
It ¼ If  νf þ Ib  νb: ð5Þ
Employing Eqs. 1, 4 and 5, we obtain the fractional saturation of FcMaytansine
needed to calculate the binding constant of its binding to the site and this of a
ligand by competition with a probe of known binding constant.
νb ¼ r  rfð Þ = r  rfð Þ þ R rb  rð Þ½ ; ð6Þ
with R representing the ratio between the fluorescence intensity of the bound and
free species (R= Ib/If). Equation 6 can be simplified with Eq. 3 in cases when there
is no change in the quantum yield (i.e., R= 1)36.
Once the fractional saturation of FcMaytansine in the experiments is known,
the free concentration of tubulin and FcMaytansine in the titration assay can be
calculated from the difference between the bound and the total concentration of the
probe. The free concentration of tubulin was calculated from the difference in the
total and bound concentration of FcMaytansine assuming a stoichiometry of 1:1.
The values of fractional saturation of FcMaytansine bound vs. the free tubulin
concentration were used to determine a binding constant at 25 °C of 1.6 ± 0.3 × 108
M−1 using SigmaPlot v13 (Systat Software, Inc., San Jose, CA, USA).
The binding constant of a problem ligand K(l) can be determined from the
known values of the binding constant of the reference ligand K(r) and the total
concentrations of binding sites, FcMaytansine and problem ligand by solving the
simultaneous mass action equations:
K lð Þ ¼ Ligand½ bound= Sites½ free Ligand½ free ð7Þ
K rð Þ ¼ FcMaytansine½ bound= Sites½ free FcMaytansine½ free ð8Þ
FcMaytansine½ free¼ FcMaytansine½ total FcMaytansine½ bound ð9Þ
Ligand½ free¼ Ligand½ total Ligand½ bound ð10Þ
Sites½ free¼ Sites½ free Ligand½ bound FcMaytansine½ bound: ð11Þ
The system was solved using EQUIGRA534 using the binding constant of
FcMaytansine and a stoichiometry of 1:1 for the tubulin–FcMaytansine complex
(EQUIGRA5 can be obtained upon request from Fernando Díaz, fer@cib.csic.es).
X-ray data collection and structure solution. Crystals of T2R–TTL were obtained
by the sitting-drop vapor-diffusion method as previously described16,17 and with a
protein ratio of 2:1.2:1.2 (tubulin/RB3/TTL). Crystals reached their maximum
dimensions within 1 week and were soaked for 1 h to overnight at 20 °C in
reservoir solution consisting of 10 % PEG 4k, 16% glycerol, 30 mM MgCl2, 30 mM
CaCl2 and 100 mM 2-(N-morpholino)ethanesulfonic acid/imidazole pH 6.7 and
containing 2 or 5 mM of compound (final DMSO concentration: 10%). Crystals
were fished directly from the drop, transferred for a few seconds to a reservoir
solution supplemented with 2 or 5 mM of compound and 20% glycerol as cryo-
protecting agent and flash-cooled in a nitrogen stream at the beamline. Standard
data collections were performed at 1 Å wavelength at 100 K at the beamline X06DA
at the Swiss Light Source (Paul Scherrer Institut, Villigen, Switzerland). Standard
data processing, structure solution using the difference Fourier method and
structure refinement were performed with the programs XDS37 and Phenix38,16,17.
All models have good geometry, with small r.m.s. deviations from ideal values for
bond lengths and bond angles. MolProbity39 analysis shows all residues in favored
or allowed regions in the Ramachandran plot (T2R–TTL–disorazole Z: 98.2/1.8%;
T2R–TTL-Spongistatin-1: 97.4/2.6%; T2R–TTL–FcMaytansine: 97.6/2.4%). Data
collection and refinement statistics are given in Table 1. Figures were prepared in
PyMol (Schrödinger, LLC).
Data availability. Data supporting the findings of this manuscript are available
from the corresponding author upon reasonable request. Coordinates of the X-ray
crystal structures have been deposited in the RCSB PDB (www.rcsb.org) under
accession numbers 6FJF (tubulin-FcMaytansine), 6FII (tubulin-spongistatin-1) and
6FJM (tubulin-disorazole Z).
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